APRE
Aprea Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$11.76M
P/E Ratio
—
EPS
$-1.49
Beta
1.52
52W High
$2.22
52W Low
$0.55
50-Day MA
$0.83
200-Day MA
$1.09
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies that reactivate the mutant p53 tumor suppressor protein. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | 123,300 |
| Gross Profit (TTM) | $-6.92M |
| EBITDA | $-12.56M |
| Operating Margin | -10202.00% |
| Return on Equity | -40.40% |
| Return on Assets | -23.20% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $3.47 |
| Price-to-Book | 0.28 |
| Price-to-Sales (TTM) | 95.41 |
| EV/Revenue | - |
| EV/EBITDA | 0.35 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -98.40% |
| Shares Outstanding | $12.38M |
| Float | $8.57M |
| % Insiders | 11.55% |
| % Institutions | 18.13% |
Historical Volatility
HV 10-Day
100.95%
HV 20-Day
89.24%
HV 30-Day
95.26%
HV 60-Day
95.55%
HV Rank
71.4%
Volatility is currently expanding
Analyst Ratings
Consensus ($4.30 target)
1
Strong Buy2
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026